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Abstract  
Introduction: Patients with advanced Heart failure (HF) experience many burdensome 
symptoms that increase patient suffering.  
Methods: Comparative secondary analysis of 347 patients with advanced HF. Symptom 
burden was measured with the Memorial Symptom Assessment Scale-HF. Depression 
was measured using the Patient Health Questionnaire-9. 
Results: Mean number of symptoms was 13.6.  The three most frequent symptoms 
were pain, shortness of breath, and lack of energy. Patients with depression reported 
higher symptom burden. Symptom burden differed when compared by gender. Women 
reported higher symptom burden for other pain, dry mouth, swelling of the arms and 
legs, sweats, feeling nervous, nausea, and vomiting. Men reported higher symptom 
burden with sexual problems.  
Conclusions: Given the high rates of symptoms and distress, interventions are needed 
to alleviate the symptom burden of patients with advanced HF. Reported symptom 
burden in patients with advanced heart failure was higher when depressive symptoms 
were present. Women reported varied number and severity of symptoms than men. 
Key Words: Advanced Heart Failure, Memorial Symptom Assessment Scale-Heart 
Failure, Depression, Pain, Gender 
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Introduction 
The number of people with heart failure (HF) continues to grow with 
approximately 6.5 million Americans being diagnosed in the years 2011-2014,1  and 
projections for the year 2030 show an increase of 46%.2 Advanced HF is associated 
with many burdensome symptoms that occur as a result of altered cardiac function and 
neurohormonal activation.3,4 One of the major goals of HF care is alleviation of 
symptoms and the associated suffering that diminishes quality of life.3 Therefore, it is 
important that symptoms are measured using a questionnaire that is valid, reliable, and 
comprehensive. The Memorial Symptom Assessment Scale for Heart Failure (MSAS-
HF) is one such questionnaire that can be used to assess the wide array of symptoms 
that patients experience.  
The frequency and severity of symptoms reported by HF patients may be 
influenced by depression level.3, 5-7 Depression has been found in approximately 22-
42% of HF patients and poses additional threats to effective advanced HF 
management.8 Depressive symptoms such as hopelessness, concentration difficulties, 
and apathy make following guideline recommendations more difficult, thus decreasing 
quality of life. In addition, patients with HF and depression have been shown to have 
57% increased rate of hospital admission.9 
While the prevalence of HF is similar for women and men, mortality rates are 
higher in women than men, demonstrating the need to include adequate numbers of 
women with HF in studies.10 The average percentage of women participating in HF 
studies remains low at 32%.11 Without adequate representation of women in studies, 
generalizability of the data to women is limited.11 
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Systematic review of symptom clusters in cardiovascular disease patients found 
the majority of the studies done with HF patients only included 8-10 symptoms with 1 
study using 14 symptoms.12 Of the six HF studies, none of them focused on patients 
with advanced HF, with the majority of the studies included patients in all NYHA 
classes.13-18 One goal of this study was to determine how many symptoms advanced 
HF patients endorse when a broader range of symptom choices are assessed.  This 
study evaluated 32 different symptoms in advanced HF patients.    
 The aims of this study were to: 1) characterize symptom burden defined as, 
presence, frequency, severity, and level of distress the symptoms provoked; 2) evaluate 
differences in symptom burden between patients with high and low depressive 
symptoms and between women and men; and 3) determine sociodemographic (i.e., 
age, gender, marital status, education), psychosocial (i.e., depression, social support), 
and clinical (ejection fraction, comorbidity) variables that explain symptom burden 
(composite of each symptom how often, severity, and distress) among patients with 
advanced HF.  
Methods 
Design, Sample, Setting 
A retrospective explanatory design was used for this study. The data were 
obtained for this comparative analysis from a multisite study Pain Assessment, 
Incidence and Nature in Heart Failure in which 347 patients with advanced HF were 
recruited from 10 different outpatient clinics and 5 home hospice programs across the 
United States who were involved with the Palliative Care-Heart Failure Education and 
Research Trials collaborative. Institutional review boards approved the original study 
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and the current study.19 All patients completed written informed consent prior to data 
collection. The purpose of the parent study was to fully evaluate pain among community 
dwelling patients with advanced HF, the impact of pain on activity and quality of life, and 
determine its relationship to health status.19 Inclusion criteria were advanced HF 
patients who were at least 18 years old. Advanced HF was defined as dyspnea or 
fatigue at rest or with minimal exertion. HF providers confirmed the presence of HF. 
Both patients with reduced and preserved ejection fraction were enrolled. Only patients 
with reduced ejection fraction (40%), needed to be receiving optimal medical therapy for 
at least one month before enrollment as recommended by the American Heart 
Association/American College of Cardiology guidelines, as there are not 
recommendations for patients with preserved ejection fraction.19 Exclusion criteria were: 
cognitive or other impairments that prevented accurate assessment of symptoms or 
resulted in inability to provide informed consent;  HF due to recent onset of acute viral or 
peripartum myocarditis; hemodialysis or mechanical ventilation; received non-approved 
Federal Drug Administration investigational agents or devices; previous cardiac 
transplantation or destination therapy with left ventricular assistive device; cor 
pulmonale or right ventricular HF in the absence of left ventricular systolic dysfunction; 
and awaiting cardiac transplantation or destination therapy with left ventricular assistive 
device.19   
The theoretical framework guiding this study is the Theory of Unpleasant 
Symptoms. In this theory, it is proposed that symptoms have antecedent factors that 
can be categorized as physiological, psychological, situational or environmental.20-21 
The symptoms are interactive and reciprocal as they relate to one another and 
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improvement of one or more symptoms may contribute to the management or 
improvement of others.21 Data to support the theory focuses on symptom timing/how 
often, intensity, duration, quality and distress experienced by the patient.21 Due to the 
high number of symptoms patients with advanced HF have reported in past studies, this 
theory provides guidance to explain symptom experience as well as improve symptom 
management by accounting for the cumulative effects of multiple symptoms.13,19  For 
example, depression magnifies pain experience, pain lengthens the time needed for 
successful treatment of depression, and concurrent pain and depression reduce a 
person’s coping skills.22   
Measures 
Symptom burden was measured using the Memorial Symptom Assessment 
Scale-HF (MSAS-HF). The MSAS-HF is based on the Memorial Symptom Assessment 
Scale, an instrument developed for patients with cancer.23 For the MSAS-HF, cancer-
specific symptoms were removed and HF-specific symptoms were added.24,25 The 
MSAS-HF is a 32-item questionnaire on which patients are asked to report how often, 
severity, and distress each symptom evoked in the past week. Individual scores are 
summed for each symptom present, rating frequency, severity, and distress to obtain a 
total symptom score for each symptom with a possible range of 0-13. MSAS-HF 
response scales are as follows: 1) symptom present 0=“no”, 1=“yes”; 2) how often 
1=“rarely”, 2=“occasionally”, 3=“frequently”, 4=“almost constantly”; 3) severity 1=“slight”, 
2=“moderate”, 3=“severe”, 4=“very severe”; and 4) distress 0=“not at all”, 1=“a little bit”, 
2=“somewhat”, 3=“quite a bit”, 4=“very much”. The total symptom scores are summed to 
obtain a final grand total symptom burden score that includes all 32 symptoms with a 
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possible score range of 0-416.23 Higher scores indicate greater symptom burden. In 
previous studies, the internal consistency of the MSAS-HF was supported by 
Cronbach’s alpha 0.92 among 52 patients recruited from a HF clinic.24,26 Content 
validity, construct validity, and internal consistency reliability were demonstrated.26 The 
MSAS-HF reliability was satisfactory in this sample with a Cronbach’s alpha of 0.90.   
Depression was measured using the Patient Health Questionnaire (PHQ-9).  The 
PHQ-9 is based on the Diagnostic and Statistical Manual of Mental Disorders for clinical 
depression diagnostic criteria.27 Patients are asked to rate each of the 9 items as to how 
often they were bothered by each symptom over the past two weeks. The items are on 
4 point response scales of 0= “not at all”, 1= “several days”, 2= “more than half the 
days”, 3= “nearly every day”. Possible scores range from 0- 27, with higher scores 
indicating greater likelihood of depression. In past studies, a total score of ≥ 10 had a 
sensitivity and specificity of 88% in diagnosis of major depression.27 Therefore, ≥ 10 
was used as the cut off for a positive screen for depression in this analysis. Construct 
validity of the PHQ-9 was supported among 308 HF patients9 and internal consistency 
was supported with Cronbach’s alpha of 0.82 among 249 patients with HF.28 The 
reliability of the PHQ-9 in this sample was satisfactory with Cronbach’s alpha of 0.85. 
 The Enriched Social Support Instrument was used to measure perceived social 
support. This instrument was developed to include items about structural, instrumental, 
and emotional support previously found to be significant predictors of mortality among 
patients with cardiovascular conditions.29 Patients were asked to rate 6 items based on 
their current situation. The item response scales include: 1 = “none of the time”, 2 = “a 
little of the time”, 3 = “some of the time”, 4 = “most of the time”, and 5 = “all of the time”. 
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On the final item, patients are asked if they are currently married or living with a partner, 
with a 4= “yes” and 2= “no”.6 Items are summed to obtain a total score with higher 
scores indicating greater perceptions of social support. Total possible scores range from 
0 to 31. Internal consistency reliability was reported with an estimated Cronbach’s alpha 
0.86, and convergent validity was supported by a moderate correlation (r=0.62) with the 
Perceived Social Support Scale among 196 myocardial infarction patients.29  Reliability 
was satisfactory in this study with a Cronbach’s alpha of 0.88.  
The Charlson Comorbidity Index is a method of evaluating comorbidities among 
patients and is based on the International Classification of Diseases diagnosis.30  
Diagnoses are included for the following conditions if they were present in the patients’ 
medical records: myocardial infarction, congestive HF, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue 
disease, ulcer disease, liver disease, moderate or severe renal disease, hemiplegia, 
leukemia, lymphoma, metastatic solid tumor, any tumor, human immunodeficiency virus 
with or without acquired immunodeficiency syndrome, and diabetes with or without end 
organ damage.30 Each comorbidity is assigned an associated weight and the sum of the 
weighted scores is the final comorbidity index score.30 Higher scores reflect more 
comorbidity burden.30 Predictive validity was supported by 3,496 community dwelling 
older adults in primary care.30  
Chart review and patient interview were used to collect data on age, sex, race, 
ethnicity, living situation, household income, education level, and left ventricular ejection 
fraction.  
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Statistical Analysis 
Descriptive statistics were used to examine sociodemographic variables and to 
describe the presence, frequency, and severity of symptoms during the previous week, 
and the level of distress the symptoms evoked. Chi-square, independent t-tests, and 
Mann-Whitney U, were computed for aim two comparing patient characteristics and 
evaluating the differences in symptom burden by depression score (PHQ-9 score < 10 
or ≥ 10) and gender.27 To determine the influence of explanatory variables on “grand 
total symptom burden,” multicollinearity and other violations of the assumptions of 
multiple regression were assessed and no violations were found. Explanatory variables 
of grand total symptom burden were then evaluated using simultaneous multiple 
regression with pairwise deletion. Independent variables entered into the regression 
model were age, gender, marital status, education level, depression score, social 
support score, ejection fraction, and comorbidity score. A post-hoc analysis was done to 
test if there was an interaction effect between depression and gender on grand total 
symptom burden. Only those patients with complete data for all study variables were 
included in the regression analysis (N=323). Significance level was set at p ≤ 0.05.  
Results 
The sample featured 35% women and 65% men, 79% White and 19% Black, and 
8% Hispanic. Fifty-five percent were married, 49% reported having more than a high 
school education, and 89% reported having a household income over $25,000 (Table 
1). The mean age of the sample was 66 years old, mean left ventricular ejection fraction 
was 30%, and the mean Charlson Comorbidity Index was 3.64. Most patients (76.6%) 
had advanced HF with reduced ejection fraction (≤ 40%), 89% were prescribed 
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diuretics, 94% were prescribed beta-blockers, 79% were prescribed angiotensin-
modulating agents, and 52% had an internal cardiac defibrillator, based on patient 
medical records. Only 8% of the patients who had reduced ejection fraction were unable 
to tolerate beta blockers and/or angiotensin-modulating agents. The mean PHQ 9 
depression score was 7.69 (SD 6.24), with 224 participants with a score less than 10 
and 105 with 10+ (Table 1). No differences in prevalence of depression was found 
between genders (p=0.221) as shown in Table 1. 
The number of symptoms present based on the MSAS-HF ranged from 0-32. 
The mean and standard deviation (SD) of the total number of symptoms reported were 
13.6 and 6.8, respectively. Each symptom reported as present by at least 50% of the 
patients in order of most common included: pain other than chest pain (77%), shortness 
of breath (76%), lack of energy (76%), feeling drowsy (62%), numbness/tingling (60%), 
dry mouth (60%), and difficulty sleeping (59%) as shown in Table 2.     
The three most frequent symptoms, pain other than chest pain, shortness of 
breath, and lack of energy had the highest mean scores for total symptom score (7.4-6), 
how often (2.5-3), severity (1.7-2), and distress (1.6-1.9) except sexual problem which 
had the third highest mean in how often (2.9) (Table 2).  
The mean MSAS-HF grand total symptom burden score was 96 (SD=58), with a 
range of 0-336, the 25th and 75th percentiles were 52 and 125, respectively. Differences 
were found in total symptom burden based on depression scores (10+ vs. <10) for 31 of 
the 32 symptoms (Table 3). Patients with higher depression scores reported higher 
symptom burden. In addition, patients with higher depression scores experienced higher 
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overall symptom burden as determined by grand total symptom burden score of 70 
versus 137 (p < 0.001). 
Compared with men, women had significantly greater symptom burden in the 
following areas: pain other than chest pain (p = 0.005), feeling nervous (p = 0.041), dry 
mouth (p = 0.022), nausea (p = 0.0.021), vomiting (p = 0.015), sweats (p = 0.043), and 
swelling of the arms and legs (p = 0.015).  Men reported significantly more symptom 
burden from sexual problems than women (p ≤ 0.001) (Table 3). No significant 
differences were found in grand total symptom burden score (p = 0.141).   
The overall multiple regression model was significant (R2 = 0.413, p < 0.001) 
when the MSAS-HF grand total symptom burden score was entered as the dependent 
variable and age, gender, marital status, education level, depression score, social 
support, left ventricular ejection fraction, and comorbidity score were entered as 
independent variables. An interaction term of depression and gender was also 
evaluated and found to be non-significant (p = 0.078). Depression and education were 
the only significant explanatory variables of the MSAS-HF grand total symptom burden 
score (Table 4) with depression accounting for most of the explained variance. Patients 
with high levels of depression had higher MSAS-HF grand total symptom burden 
scores, meaning that those with higher depression levels reported greater symptom 
burden. Compared with patients with education level of more than high school, patients 
with high school education level or less had lower grand total symptom burden 
indicating that patients with lower education levels reported less symptom burden.  
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Discussion 
Patients with advanced HF reported a large number of symptoms (mean 13.6 
with SD 6.8) with moderate burden levels despite the majority (92%) of patients 
receiving optimal medical management of HF. In another study, investigators reported 
that patients with advanced HF had a similar number of symptoms (12, SD=5.8) using 
the MSAS-HF.31 They reported the same top 6 symptoms as the current study found 
despite a smaller sample (N=40).31 With the mean number of 12 and 13.6 symptoms 
being reported in each study, additional research looking at symptoms clusters is likely 
needed as only 6-9 symptoms were assessed in previous HF symptom cluster 
work.13,17,32,33 Key information that would further inform clinical practice maybe missing 
due to the few number of symptoms included. Additional research investigating 
symptoms clusters using a measure of more symptoms with the inclusion of pain and 
depression is needed.  
The most commonly reported symptom in this study was pain other than chest 
pain (77%).19 This finding is a somewhat surprising because the hallmark symptoms of 
HF are shortness of breath and lack of energy.34-36 Non-cardiac pain has been 
investigated in HF patients because of the impact of comorbidities on HF patients and 
the corresponding increase in symptom burden.37-41 This study supports the need for 
additional non-cardiac pain assessment and proper treatment among patients with 
advanced HF.  
The next most commonly reported symptoms were shortness of breath and lack 
of energy, both with an overall presence of 76% is consistent with existing scholarly 
literature. Wilson and colleagues found both symptoms to be among the three most 
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commonly reported with shortness of breath at 65%, and lack of energy at 70%.31 By 
definition, advanced HF occurs when symptoms are present at rest despite optimal 
medical therapy.4 More research is needed to understand how to optimize management 
of shortness of breath and exertional fatigue to reduce symptom burden to more 
manageable levels.42  
Not surprisingly, in addition to being more frequent, pain other than chest pain, 
shortness of breath, and lack of energy were most severe, and distressing symptoms; 
therefore, they were the most burdensome among these patients with advanced HF.  
Wilson and colleagues found similar results among patients with HF enrolled in hospice, 
with seven of the most common symptoms being the same symptoms reported in the 
current study.31 Differences between Wilson’s study and the current study included 
symptoms of weight loss (20% vs 53%) and change in taste (23% vs 50%).31 It is 
unclear why the percentage of patients reporting weight loss and change in taste is 
higher in the current study. One possible explanation is that the sample size was larger 
in the current study, or patients maybe have been on different medication regimens. 
The sample size in the current study was larger and the majority of patients (92%) were 
prescribed optimal medical treatment for HF.43, 44 
 Results from the current study demonstrated that patients with higher depression 
scores reported higher symptom burden. This important result is consistent with the 
theory and past studies as discussed in the introduction section.3,5,7,45 In addition to 
assessing for expected and unexpected HF symptoms, using a valid depression 
screening tool (such as the PHQ 9) is important for all HF patients, particularly those 
patients with advanced HF where rates of depression are highest.  
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The prevalence of depression was not different between genders (p=0.221) in 
our study, which is different from previous studies in people with myocardial infarction.46 
Recent estimates from the CDC of men and women living in the United States, aged 
51+ with clinically significant depressive symptoms, ranged between 9-14% in men and 
15-19% in women, between the years 2006-2014.47 Similar findings are available for 
European countries although differing methods of measurement used by different 
countries make generalized estimates of major depression more difficult.46 While 
depressive symptoms have many of the same risk factors as the general population 
(e.g., stressful life events), gender is only a significant predictor of depression in some 
studies.46 
 Symptoms of significance varied by gender, although grand total symptom 
burden did not. Women were more likely to report higher scores of other pain, feeling 
nervous, dry mouth, nausea, vomiting, sweats, and swelling of the arms and legs. This 
finding suggests that women may require more extensive or different treatment options 
and requires further exploration. Further research is also needed to determine if women 
experience more symptoms at all stages of HF or just with advanced HF.   
 The issue of sexual problems in HF can include erectile dysfunction, orgasmic 
difficulties, lack of interest in sex, being afraid to have sex, and partner fear of having 
sex.48 Of the studies involving sexual dysfunction in HF, no gender differences were 
found that would explain the differences in reporting we have found here, as both 
genders reported problems in other studies.49 One explanation maybe that only those 
who have a sexual partner may report having a sexual issue and many of the women in 
this study were not married where as more of the men were (p≤0.001).50   
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Depression and education were significant explanatory variables of higher grand 
total symptom burden. It is possible those with lower level of education reported less 
symptoms due to lower health literacy or inability to express their symptoms 
accurately.33 The more important finding of the study is a substantial part of the variance 
(41%) in grand total symptom burden was accounted for by depression. Thus, the 
clinical implication is by treating depressive symptoms we may improve patients overall 
symptom burden. 
Limitations 
 This study has a few limitations. First, the sample was comprised of mainly White 
patients and results may not be generalizable to patients from other racial groups. 
Second, the sample was comprised of unequal numbers of women and men. The 
greater percentage of men may have influenced results. Third, the majority (92%) of the 
patients in this study with reduced EF were prescribed optimal medical therapies and 
results may not be generalizable to patients who are not prescribed these therapies.  
Finally, there were multiple significance testing completed on the 32 items of the MSAS-
HF, which may have influenced the study findings. These results need to be confirmed 
in a prospective study among a more diverse group of patients.  
Conclusion 
The results of this study suggest a need to test the impact of clinical assessment 
including wider variety of symptoms in patients with advanced HF, and of clinical 
interventions aimed at effectively managing the high symptom burden. Given the high 
rates of symptoms and associated distress, novel interventions need to be developed 
and tested to alleviate the symptom burden of patients with advanced HF. Furthermore, 
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lack of energy was reported as the most bothersome symptom and little is known about 
how to treat fatigue (or lack of energy) in advanced HF. Knowing the frequency and 
overall burdensome nature of multiple symptoms is important for future interventions, as 
many symptoms were present despite optimal medical management of HF. Additional 
research focusing on the reciprocal nature of multiple symptoms is also needed by 
expanding on symptom cluster work by adding assessment of additional symptoms.  
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Table 1: Sociodemographic characteristics for total sample and compared by depression and gender 
 
Variable 
Total 
n or mean/SD*** 
PHQ-9 (<10) 
n or mean/SD 
PHQ-9 (10+) 
n or mean/SD 
Male 
n or mean/SD 
Female 
n or mean/SD 
Gender 
   Male 
   Female 
 
222 
123 
 
148 
76 
 
62 
43 
 
 
 
 
Race** 
   White 
   Other 
 
225 
72 
 
164 
43 
 
80 
23 
 
172 
37 
 
81 
34 
Household Income** 
   <25,000 
   25,000+ 
 
154 
139 
 
102 
91 
 
44 
43 
 
84 
102 
 
70 
35 
Education** 
   High School or less 
   More than High School 
 
168 
158 
 
119 
98 
 
43 
52 
 
95 
109 
 
71 
48 
Marital Status** 
   Not Married 
   Married 
 
158 
190 
 
109 
116 
 
40 
66 
 
80 
142 
 
77 
46 
Ethnicity 
   Hispanic 
   Not Hispanic 
 
23 
305 
 
18 
194 
 
5 
94 
 
13 
192 
 
10 
104 
Age* 66.26 (14.86) 68.61 (14.65) 61.61 (13.71) 66.11 (13.99) 66.77 (16.17) 
Left Ventricular Ejection 
Fraction** 
   40+ 
   <40 
0.30 (0.15) 
 
72 
262 
0.293 (0.14) 0.32 (0.15) 0.28 (0.13) 0.34 (0.17) 
Social Support* 22.94 (5.18) 23.52 (4.81) 21.87 (2.17) 22.99 (5.49) 22.80 (4.56) 
Charlson Comorbidity 
Index 
3.64 (2.22) 3.62 (2.17) 3.72 (2.25) 3.59 (2.24) 3.75 (2.19) 
PHQ 9 
   <10 
   10+ 
7.69 (6.24) 
224 
105 
 
 
 
 
  
*Significant difference in depression scores p-value ≤0.05, **Significant difference in gender p-value ≤0.05, ***SD = standard deviation 
Table 2: Symptom frequency, severity and distress in order of most reported to leasta (n= 326) 
 
 Symptom Overall 
Presence 
n (%) 
Total score 
Range 0-13 
Mean (SD2) 
How often 
Range 1-4 
Mean (SD) 
How severe 
Range 1-4 
Mean (SD)   
Distress 
Range 0-4 
Mean (SD) 
1 Other pain 251 (77) 6.5 (4.2) 2.9 (.9) 1.8 (1.2) 1.8 (1.4) 
2 Shortness of breath 248 (76) 6.0 (4.1) 2.5 (.9) 1.7 (1.2) 1.6 (1.4) 
3 Lack of energy 248 (76) 7.4 (4.1) 3.0 (.9) 2.0 (1.2) 1.9 (1.5) 
4 Feeling drowsy 202 (62) 4.5 (4.1) 2.5 (.9) 1.3 (1.2) 1.0 (1.3) 
5 Numbness/tingling 196 (60) 4.5 (4.4) 2.6 (1.0) 1.3 (1.3) 1.1 (1.4) 
6 Dry mouth 196 (60) 4.3 (4.3) 2.6 (1.0) 1.2 (1.2) 1.0 (1.4) 
7 Difficulty sleeping 192 (59) 5.1 (4.7) 2.7 (1.0) 1.4 (1.4) 1.4 (1.5) 
8 Difficulty breathing when lying flat 160 (49) 3.0 (3.5) .5 (.5) 1.3 (1.6) 1.2 (1.6) 
9 Worrying 157 (48) 3.7 (4.3) 1.2 (1.4) 1.0 (1.2) 1.0 (1.3) 
10 Cough 157 (48) 3.6 (3.6) 2.2 (.9) 1.0 (1.0) .7 (1.1) 
11 Difficulty concentrating 157 (48) 3.2 (3.8) 2.2 (.9) .8 (1.0) .8 (1.3) 
12 Swelling of arms and legs 147 (45) 2.0 (2.6) 0 .9 (1.1) .7 (1.2) 
13 Feeling bloated 147 (45) 3.4 (4.2) 2.3 (1.0) .9 (1.2) .9 (1.4) 
14 Sweats 143 (44) 2.4 (3.7) 2.2 (.9) .7 (1.1) .5 (1.1) 
15 Feeling sad 143 (44) 3.0 (3.9) 2.1 (.9) .8 (1.1) .8 (1.2) 
16 Dizziness 140 (43) 3.1 (3.9) 2.1 (.8) .8 (1.1) .8 (1.3) 
17 Feeling irritable 140 (43) 2.8 (3.7) 2.0 (.8) .8 (1.1) .7 (1.2) 
18 Chest pain 134 (41) 2.8 (3.8) 1.9 (.8) .8 (1.2) .8 (1.3) 
19 Palpitations 127 (39) 1.8 (3.2) 2.0 (.8) .5 (.9) .4 (1.0) 
20 Feeling nervous 124 (38) 2.5 (3.6) 2.2 (.9) .7 (1.0) .7 (1.2) 
21 Itching 117 (36) 2.5 (3.7) 2.2 (.9) .7 (1.0) .6 (1.1) 
22 Sexual problems 111 (34) 3.1 (4.8) 2.9 (1.1) .9 (1.5) .9 (1.5) 
23 Lack of appetite 108 (33) 2.2 (3.5) 2.3 (1.1) .7 (1.1) .4 (1.0) 
24 Waking up breathless 108 (33) 2.4 (3.9) 2.2 (1.) .7 (1.1) .7 (1.3) 
25 Weight gain 104 (32) 1.5 (2.5) .29 (.5) .6 (1.0) .6 (1.2) 
26 Urination problem 104 (32) 2.3 (3.8) 2.4 (1.4) .6 (1.1) .6 (1.2) 
27 Nausea 101 (31) 2.0 (3.4) 2.0 (1.0) .6 (1.0) .5 (1.1) 
28 Diarrhea 78 (24) 1.6 (3.2) 1.9 (.8) .5 (1.0) .4 (1.0) 
29 Food taste change 75 (23) 1.2 (2.4) 0 .5 (1.0) .4 (1.0) 
30 Weight loss 65 (20) 0.7 (1.7) 0 .4 (.8) .2 (.7) 
31 Constipation 62 (19) 1.4 (2.5) 0 .6 (1.0) .6 (1.1) 
32 Vomiting 39 (12) .8 (2.4) 1.8 (.9) .2 (.7) .2 (.8) 
aHigher number indicates higher frequency, severity, and distress. 2SD = standard deviation, bold=top 3 highest 
Table 3. MSAS-HFa symptom total scores compared by depression and gender 
  Depression Gender 
Symptom Not 
Depressed 
(N=225) 
Median 
(25,75 
percentile) 
Depressed 
10+ (N=106) 
Median 
(25,75 
percentile) 
P 
Value 
=/≤ 
Male 
(N=222) 
Median 
(25,75 
percentile) 
Female 
(N=123) 
Median 
(25,75 
percentile) 
P value 
=/≤ 
Difficulty 
Concentrating 
0 (0,4) 6.5 (0,9) 0.001 0 (0,6) 3 (0,7) 0.063 
Chest Pain 0 (0,5) 1 (0,8) 0.002 0 (0,6) 0 (0,6) 0.538 
Other Pain 7 (0,9) 9 (6,11) 0.001 7 (0,9) 8 (6,10) 0.005 
Cough 3 (0,5) 4.5 (0,8) 0.001 4 (0,6) 3 (0,6) 0.424 
Feeling Nervous 0 (0,4) 1 (0,7) 0.001 0 (0,5) 0 (0,6) 0.041 
Dry Mouth 3 (0,7) 5.5 (2,9) 0.001 4 (0,7) 5 (0,9) 0.022 
Nausea 0 (0,0) 0 (0,7) 0.001 0 (0,3) 0 (0,5) 0.021 
Feeling Drowsy 4 (0,7) 7 (0,9) 0.001 0 (0,8) 0 (0,9) 0.541 
Numbness 
Tingling 
3 (0,7) 7 (0,10) 0.001 5 (0,9) 5 (0,8) 0.973 
Difficulty Sleeping 3 (0,8) 9 (0,11) 0.001 6 (0,10) 5 (0,9) 0.830 
Feeling bloated 0 (0,6) 5 (0,9) 0.001 0 (0,6) 0 (0,7) 0.173 
Urination Problem 0 (0,3) 0 (0,6) 0.017 0 (0,5) 0 (0,3) 0.152 
Palpitations 0 (0,0) 0 (0,6) 0.001 0 (0,3) 0 (0,4) 0.317 
Lack of Energy 7 (4,10) 10 (7,12) 0.001 8 (5,10) 8 (6,11) 0.251 
Waking up 
Breathless 
0 (0,0) 0 (0,8) 0.001 0 (0,5) 0 (0,4) 0.916 
Vomiting 0 (0,0) 0 (0,1) 0.001 0 (0,0) 0 (0,0) 0.015 
Shortness of Breath 6 (0,8) 9 (6,10) 0.001 7 (3,9) 6 (3,9) 0.795 
Diarrhea 0 (0,0) 0 (0,4) 0.004 0 (0,0) 0 (0,0) 0.933 
Feeling Sad 0 (0,4) 6.5 (0,9) 0.001 0 (0,6) 0 (0,6) 0.655 
Sweats 0 (0,3) 0 (0,7) 0.001 0 (0,4) 0 (0,6) 0.043 
Worrying 0 (0,5) 7 (0,10) 0.001 0 (0,7) 5 (0,8) 0.089 
Sexual Problems 0 (0,3) 3 (0,11) 0.001 0 (0,9) 0 (0,0) 0.001 
Itching 0 (0,4) 0 (0,6) 0.008 0 (0,5) 0 (0,5) 0.471 
Lack of Appetite 0 (0,0) 3 (0,7) 0.001 0 (0,4) 0 (0,5) 0.257 
Dizziness 0 (0,5) 5 (0,7) 0.001 0 (0,7) 0 (0,6) 0.569 
Feeling Irritable 0 (0,4) 5 (0,9) 0.001 0 (0,6) 0 (0,6) 0.945 
Food Taste Change 0 (0,0) 0 (0,3) 0.056b 0 (0,0) 0 (0,3) 0.119 
Weight Loss 0 (0,0) 0 (0,2) 0.001 0 (0,0) 0 (0,0) 0.115 
Constipation 0 (0,0) 0 (0,4) 0.003 0 (0,1) 0 (0,4) 0.111 
Swelling of Arms and 
Legs 
0 (0,3) 2( 0,5) 0.014 0 (0,3) 2 (0,4) 0.015 
Weight Gain 0 (0,2) 0 (0,6) 0.001 0 (0,3) 0 (0,3) 0.758 
Difficulty breathing 
when lying flat 
0 (0,5) 5 (0,8) 0.001 0 (0,6) 2 (0,7) 0.321 
MSAS-HF  
Grand Total 
70 (42,106) 137 (95,180) 0.001 86 (49,125) 90 (67,125) 0.141 
aMSAS-HF = Memorial Symptom Assessment Scale-Heart Failure, bonly symptom not sig for depression analysis, 
bold= significant gender difference variables 
Table 4: Multiple regression analysis for total symptom burden score (n=326)a  
   
Variable B Standard Error 
B 
β t 
 
 
P-value 
Age -0.171 0.199 -0.044 -0.862 0.389 
Gender 
0=male 
1=female 
0.025 5.794 0.000 0.004 0.997 
Marital status 
0=not married 
1= married 
-3.119 6.024 -0.027 -0.518 0.605 
Education  
1=HS or less 
2= more than HS 
-13.063 5.288 -0.112 -2.470 0.014 
Depression 5.890 0.447 0.632 13.168 ≥ 0.001 
Social Support -0.241 0.571 -0.021 -0.421 0.674 
LVEF 27.274 19.038 0.068 1.433 0.153 
Charlson Comorbidity 
Index 
1.123 1.224 0.043 0.918 0.359 
aOverall R2 =.428, adjusted R2 =.413, F (8, 292) = 28.364, p < 0.001, MSAS-HF Grand total score regressed 
on 8 factors 
